The effect of Lu AG09222 on PACAP38- and VIP-induced vasodilation, heart rate increase, and headache in healthy subjects: an interventional, randomized, double-blind, parallel-group, placebo-controlled study

• Published in: Journal of headache and pain Vol. 24; no. 1; pp. 60 - 12
• Main Authors: Rasmussen, Nadja Bredo, Deligianni, Christina, Christensen, Casper Emil, Karlsson, William Kristian, Al-Khazali, Haidar Muhsen, Van de Casteele, Tom, Granhall, Charlotte, Amin, Faisal Mohammad, Ashina, Messoud
• Format: Journal Article
• Language: English
• Published: Milan Springer Milan 25.05.2023; Springer Nature B.V; BMC
• Subjects: Antibodies, Monoclonal, Humanized - therapeutic use; Arteries; Blood flow; Double-Blind Method; Double-blind studies; Headache; Headaches; Healthy Volunteers; Heart Rate; Humans; Internal Medicine; Medicine; Medicine & Public Health; Migraine; Migraine disorders; Migraine Disorders - therapy; Migraine treatment; Monoclonal antibodies; Monoclonal antibody; Neurology; Pain Medicine; Pituitary Adenylate Cyclase-Activating Polypeptide; Placebos; Vasoactive agents; Vasoactive Intestinal Peptide; Vasodilation; Pituitary adenylate cyclase-activating polypeptide; Migraine disorders; Monoclonal antibody; Migraine; Migraine treatment

Background Pituitary adenylate cyclase-activating polypeptide (PACAP), structurally related to vasoactive intestinal peptide (VIP), is one of the important mediators in the pathogenesis of migraine and is known to dilate cranial arteries and induce headache and migraine. Our objective was to determi...